Compare Incyte Corporation (INCY) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oxford Lane Capital Corp — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while Oxford Lane Capital Corp trades at $9.53 (market cap $909.61M). The key difference: Incyte Corporation is far larger — about 27× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OXLC | |
|---|---|---|
Market Cap | $24.54B | $909.61M |
Sector | Health | Financials |
52-Week High | $129.93 | $18.75 |
52-Week Low | $81.66 | $8.15 |
Enterprise Value | $20.04B | — |
Dividend Yield | — | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
OXLC trades at $9.52, up 2.7% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 and a high P/S of 92.8, with recent earnings misses in Q1 and Q2 2026. Dividend payments of $0.20 per share continue monthly, supported by positive net cash flow of $252.37M in 2025. Revenue declined sharply to -$580M in 2026 from $57M in 2025, raising sustainability concerns.
Outlook is cautious due to volatile earnings and high yield risks; analyst consensus is split with 50% buy ratings. Key risks include negative ROE/ROA and potential NAV decay. Opportunities exist if dividend stability persists amid market discounts, but investor vigilance on financial health is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
